Month: November 2022

On July 23, 1987, Streuff, Bernd; Luchtenberg, Helmut published a patent.Electric Literature of 86393-32-0 The title of the patent was Pharmaceutical ciprofloxacin preparations. And the patent contained the following:

Pharmaceutical oral compositions contain ciprofloxacin 30.0-95.0, cellulose-based dry binder 4.5-25.0, disintegration enhancers based on starch 0-30.0 and based on cellulose derivatives and(or) polyvinyl pyrrolidone 0.5-10.0, a flowability improver 0-2.0, and a lubricant 0-3.0 weight % for optimal biol. availability and drug stability. Tablets contained ciprofloxacin.H2O 583, Avicel 55, corn starch 72, Polyplasdone XL 30, Aerosil (unpressurized) 5, and Mg stearate 5 mg, coated with Polywax 400 200, HPM-cellulose 6.2, and TiO2 2.0 mg. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Electric Literature of 86393-32-0

The Article related to ciprofloxacin oral pharmaceutical antibacterial, enterobacteria ciprofloxacin oral pharmaceutical, Pharmaceuticals: Formulation and Compounding and other aspects.Electric Literature of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On November 28, 1996, Ali, Yusuf; Jani, Rajni published a patent.Application In Synthesis of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the patent was Antibacterial ophthalmic compositions containing synergistic combination of ciprofloxacin and a polystyrene sulfonic acid polymer. And the patent contained the following:

Aqueous pharmaceutical compositions containing a synergistic combination of ciprofloxacin (I) and a polystyrene sulfonic acid polymer (PSSA) (Markush structure given) are described, wherein the compositions are clear solutions which are comfortable and have sustained-release action. An ophthalmic pharmaceutical solution contained I.HCl.H2O (equivalent to 0.3% as base) 0.35, mannitol 4.4, boric acid 0.3, NaOH and/or HCl 0.3%, 2% PSSA solution 50, and water q.s. 100 mL. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Application In Synthesis of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to antibacterial ophthalmic pharmaceutical synergism ciprofloxacin, polystyrene sulfonic acid polymer ophthalmic pharmaceutical, Pharmaceuticals: Formulation and Compounding and other aspects.Application In Synthesis of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Puga, Ana M.; Rey-Rico, Ana; Magarinos, Beatriz; Alvarez-Lorenzo, Carmen; Concheiro, Angel published an article in 2012, the title of the article was Hot melt poly-ε-caprolactone/poloxamine implantable matrices for sustained delivery of ciprofloxacin.Application of 86393-32-0 And the article contains the following content:

It has been suggested that prevention and treatment of osteomyelitis could be achieved through local drug delivery using implantable devices, which provide therapeutic levels at the infection site with min. side-effects. Phys. blends of polycaprolactone (PCL) and poloxamine (Tetronic) were prepared by applying a solvent-free hot melting approach to obtain cytocompatible implants with a tunable bioerosion rate, ciprofloxacin release profile and osteoconductive features. Differential scanning calorimetry and X-ray anal. indicate that the hydrophilic poloxamine varieties T908, T1107, and T1307 are miscible with PCL, while the hydrophobic block copolymer T1301 is immiscible. Incorporation of the block copolymer at weight ratios ranging from 25 to 75 weight% led to matrixes with viscoelastic parameters in the range of those of fresh cortical bone. Once immersed in buffer the matrixes underwent a similar weight loss in the first week to the content of poloxamine, followed by a slower erosion rate due to PCL. The initial rapid erosion and the increase in porosity partially explain the observed burst of ciprofloxacin release, which is more intense in the PCL:T1301 formulation due to drug/T1301 repulsion due to polarity. The matrixes sustained ciprofloxacin release for several months (<50% released after 3 mo) and showed in vitro efficacy against Staphylococcus aureus, eradicating the bacteria in less than 48 h. PCL:poloxamine was cytocompatible with osteoblasts and the matrixes prepared with low proportions of T908 were also compatible with mesenchymal stem cell differentiation to osteoblasts. The influence of the nature and proportion of temperature-responsive poloxamine on the performance of PCL implantable systems was determined The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Application of 86393-32-0

The Article related to polycaprolactone tetronic dissolution hot melting ciprofloxacin hydrochloride monohydrate antibacterial, osteogenic sarcoma osteogenesis, Pharmaceuticals: Formulation and Compounding and other aspects.Application of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On September 30, 2019, Ling, Junhong; Mangal, Sharad; Park, Heejun; Wang, Shaoning; Cavallaro, Alex; Zhou, Qi Tony published an article.Related Products of 86393-32-0 The title of the article was Simultaneous Particle Size Reduction and Homogeneous Mixing to Produce Combinational Powder Formulations for Inhalation by the Single-Step Co-Jet Milling. And the article contained the following:

Homogeneous mixing of 2 cohesive jet-milled drug powders is a challenge for pharmaceutical manufacturing on account of their cohesive nature resulting in the formation of strong and random agglomerates. In this study, colistin and ciprofloxacin were co-jet milled to develop combinational antibiotic dry powder formulations for inhalation. The properties of particle size, morphol., content uniformity, and in vitro aerosolization were evaluated. The distribution of 2 drugs in the co-jet milled powders was assessed using time-of-flight-secondary ion mass spectrometry. The co-jet milled powders demonstrated an acceptable content uniformity indicating homogeneity. In general, time-of-flight-secondary ion mass spectrometry images showed relatively homogeneous distributions of ciprofloxacin and colistin in the co-milled formulations. Importantly, the 2 drugs generally had the similar fine particle fraction and deposition behavior in each combinational formulation supporting that the particle mixtures were relatively homogenous and could maximize the antimicrobial synergy. In conclusion, co-jet milling could be a viable technique to produce the combination powders for inhalation. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Related Products of 86393-32-0

The Article related to antibiotic ciprofloxacin colistin inhalation powder formulation jet milling, aerosol performance, dry powder inhaler, jet milling, mixing, uniformity, Pharmaceuticals: Formulation and Compounding and other aspects.Related Products of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On September 4, 2018, Shetty, Nivedita; Ahn, Patricia; Park, Heejun; Bhujbal, Sonal; Zemlyanov, Dmitry; Cavallaro, Alex; Mangal, Sharad; Li, Jian; Zhou, Qi Tony published an article.Related Products of 86393-32-0 The title of the article was Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin. And the article contained the following:

This study aimed to develop dry powder inhaler (DPI) combination formulations of ciprofloxacin and colistin for use in respiratory infections. Effects of colistin on phys. stability and aerosolization of spray-dried ciprofloxacin were examined The combination DPI formulations were produced by co-spray drying colistin and ciprofloxacin in mass ratios of 1:1, 1:3, and 1:9. Colistin and ciprofloxacin were also co-sprayed with L-leucine in the mass ratio of 1:1:1. The phys. and aerosolization stability of the selected co-sprayed formulations stored at 20, 55, and 75% relative humidity (RH) were examined Formulation characterizations were carried out using powder X-ray diffraction (PXRD) for crystallinity, SEM for morphol. and particle size distribution, and dynamic vapor sorption for moisture sorption. Particle surface anal. was performed using XPS, energy dispersive X-ray spectrometry, and nano-time-of-flight secondary ion mass spectrometry. Potential intermol. interactions were studied using Fourier-transform IR spectroscopy (FTIR). Aerosol performance was evaluated using a multistage liquid impinger with a RS01 monodose inhaler device. PXRD diffractograms showed that the co-spray-dried colistin-ciprofloxacin formulation in the mass ratio (1:1) was amorphous at 55% RH for up to 60 days; whereas the co-spray-dried colistin-ciprofloxacin (1:3) and colistin-ciprofloxacin (1:9) crystallized after storage for 3 days at 55% RH. However, the extent of crystallization for the combination formulations was less as compared to the spray-dried ciprofloxacin alone formulation. Surface morphol. of the co-spray-dried formulations at different concentrations did not change even after storage at 55% RH for 60 days, unlike the spray-dried ciprofloxacin alone powder which became rougher after 3 days of storage at 55% RH. Surface anal. data indicated surface enrichment of colistin in the co-spray-dried formulations. Increasing colistin concentration on the composite particles surfaces improved aerosol performance of ciprofloxacin. FTIR data demonstrated intermol. interactions between colistin and ciprofloxacin, thereby delaying and/or preventing crystallization of ciprofloxacin when co-spray-dried. Co-spray drying ciprofloxacin with colistin in the mass ratio (1:1) completely prevented crystallization of ciprofloxacin at 55% RH for up to 60 days. However, the colistin-ciprofloxacin formulation (1:1) began to fuse when stored at 75% RH due to moisture absorption resulting in a compromised aerosol performance. In contrast, the colistin-ciprofloxacin-leucine (1:1:1) formulation demonstrated no particle fusion, enabling a stable aerosol performance at 75% RH for 7 days. This study demonstrated that incorporation of colistin in the spray-dried formulations can improve phys. stability and aerosolization of amorphous ciprofloxacin at 55% RH. At 75% RH, further addition of L-leucine in the formulation prevented particle fusion and deterioration in aerosol performance, attributed to the enrichment of nonhygroscopic L-leucine on the particle surface. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Related Products of 86393-32-0

The Article related to stability inhalant ciprofloxacin colistin powder synergy, aerosol performance, co-spray drying, dry powder inhaler, multidrug resistance, storage humidity, Pharmaceuticals: Formulation and Compounding and other aspects.Related Products of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On June 10, 2018, Shetty, Nivedita; Park, Heejun; Zemlyanov, Dmitry; Mangal, Sharad; Bhujbal, Sonal; Zhou, Qi published an article.Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the article was Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation. And the article contained the following:

The aim of this study is to investigate the influence of excipients on phys. and aerosolization stability of spray dried Ciprofloxacin dry powder inhaler formulations. The model drug, Ciprofloxacin hydrochloride, was co-spray dried with excipients such as disaccharides (sucrose, lactose, trehalose), mannitol and L-leucine. The spray dried samples were stored at two different relative humidity (RH) conditions of: (1) 20% and (2) 55% RH at 20°C. Ciprofloxacin co-spray dried with disaccharides and L-leucine in the mass ratio of 1:1 demonstrated an increase in fine particle fraction (FPF) as compared with the spray dried Ciprofloxacin alone when stored at 20% RH. However, deterioration in FPF of Ciprofloxacin co-spray dried with disaccharide and mannitol was observed upon storage at 55% RH as compared to the corresponding formulations stored at 20% RH due to particle agglomeration. Whereas, 10% and 50% weight/weight L-leucine in the formulation showed no change in aerosol performance (FPF of 71.1±3.5% and 79.5±3.1%, resp.) when stored at 55% RH for 10 days as compared to 20% RH (FPF of 68.1±0.3% and 73.6±7.1%, resp.). L-Leucine demonstrated aerosolization stability by alleviating crystallization of Ciprofloxacin to some extent and preventing significant change in particle morphol. L-Leucine is well-recognized as aerosolization enhancer; our study has shown L-leucine is also a phys. and aerosolization stabilizer for spray dried Ciprofloxacin DPI formulations. Such stability enhancing activities were attributed to the enrichment of L-leucine on the particle surface as confirmed by XPS data, and intermol. interactions between L-leucine and Ciprofloxacin as measured by FT-IR. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to excipient aerosolization spray drying powder formulation inhalation, antibiotics, dry powder inhaler (dpi), excipients, fine particle fraction (fpf), spray drying, Pharmaceuticals: Formulation and Compounding and other aspects.Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 15, 2021, Chakraborty, Goutam; Patail, Nabeela Khan; Hirani, Rahim; Nandakumar, Subhiksha; Mazzu, Ying Z.; Yoshikawa, Yuki; Atiq, Mohammad; Jehane, Lina E.; Stopsack, Konrad H.; Lee, Gwo-Shu Mary; Abida, Wassim; Morris, Michael J.; Mucci, Lorelei A.; Danila, Daniel; Kantoff, Philip W. published an article.HPLC of Formula: 380843-75-4 The title of the article was Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality in BRCA2-altered prostate tumors. And the article contained the following:

Alterations in DNA damage repair (DDR) pathway genes occur in 20%-25% of men with metastatic castration-resistant prostate cancer (mCRPC). Although PARP inhibitors (PARPis) have been shown to benefit men with mCRPC harboring DDR defects due to mutations in BRCA1/2 and ATM, addnl. treatments are necessary because the effects are not durable. We performed transcriptomic anal. of publicly available mCRPC cases, comparing BRCA2 null with BRCA2 wild-type. We generated BRCA2-null prostate cancer cells using CRISPR/Cas9 and treated these cells with PARPis and SRC inhibitors. We also assessed the antiproliferative effects of combination treatment in 3D prostate cancer organoids. We observed significant enrichment of the SRC signaling pathway in BRCA2-altered mCRPC. BRCA2-null prostate cancer cell lines had increased SRC phosphorylation and higher sensitivity to SRC inhibitors (e.g., dasatinib, bosutinib, and saracatinib) relative to wild-type cells. Combination treatment with PARPis and SRC inhibitors was antiproliferative and had a synergistic effect in BRCA2-null prostate cancer cells, mCRPC organoids, and Trp53/Rb1-null prostate cancer cells. Inhibition of SRC signaling by dasatinib augmented DNA damage in BRCA2-null prostate cancer cells. Moreover, SRC knockdown increased PARPi sensitivity in BRCA2-null prostate cancer cells. This work suggests that SRC activation may be a potential mechanism of PARPi resistance and that treatment with SRC inhibitors may overcome this resistance. Our preclin. study demonstrates that combining PARPis and SRC inhibitors may be a promising therapeutic strategy for patients with BRCA2-null mCRPC. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).HPLC of Formula: 380843-75-4

The Article related to human prostate tumor brca src kinase parp inhibitor, Mammalian Pathological Biochemistry: Oncology and other aspects.HPLC of Formula: 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Janssen, Lando; Blijlevens, Nicole M. A.; Drissen, Meggie M. C. M.; Bakker, Esmee A.; Nuijten, Malou A. H.; Janssen, Jeroen J. W. M.; Timmers, Silvie; Hopman, Maria T. E. published an article in 2021, the title of the article was Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity.COA of Formula: C26H29Cl2N5O3 And the article contains the following content:

Fatigue is a common side effect of tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML). However, the prevalence of TKI-induced fatigue remains uncertain and little is known about predictors of fatigue and its relationship with phys. activity. In this study, 220 CML patients receiving TKI therapy and 110 genderand age-matched controls completed an online questionnaire to assess fatigue severity and fatigue predictors (Part 1). In addition, phys. activity levels were objectively assessed for 7 consecutive days in 138 severely fatigued and non-fatigued CML patients using an activity monitor (Part 2). We demonstrated that the prevalence of severe fatigue was 55.5% in CML patients and 10.9% in controls (P<0.001). We identified five predictors of fatigue in our CML population: age (odds ratio [OR] 0.96, 95% confidence interval [95% CI]: 0.93-0.99), female gender (OR 1.76, 95% CI: 0.92-3.34), Charlson Comorbidity Index (OR 1.91, 95% CI: 1.16-3.13), the use of comedication known to cause fatigue (OR 3.43, 95% CI: 1.58-7.44), and phys. inactivity (OR of moderately active, vigorously active and very vigorously active compared to inactive 0.43 (95% CI: 0.12-1.52), 0.22 (95% CI: 0.06-0.74), and 0.08 (95% CI: 0.02-0.26), resp.). Objective monitoring of activity patterns confirmed that fatigued CML patients performed less phys. activity of both light (P = 0.017) and moderate to vigorous intensity (P = 0.009). In fact, compared to the non-fatigued patients, fatigued CML patients performed 1 h less of phys. activity per day and took 2,000 fewer steps per day. Our findings facilitate the identification of patients at risk of severe fatigue and highlight the importance of setting reduction of fatigue as a treatment goal in CML care. This study was registered at The Netherlands Trial Registry, NTR7308 (Part 1) and NTR7309 (Part 2). The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).COA of Formula: C26H29Cl2N5O3

The Article related to fatigue cml tyrosine kinase inhibitor therapy phys activity, Mammalian Pathological Biochemistry: Oncology and other aspects.COA of Formula: C26H29Cl2N5O3

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Fan, Mengtian; Wu, Jinghong; Li, Xian; Jiang, Yingjiu; Wang, Xiaowen; Bie, Mengjun; Weng, Yaguang; Chen, Sicheng; Chen, Bin; An, Liqin; Zhang, Menghao; Huang, Gaigai; Zhu, Mengying; Shi, Qiong published an article in 2021, the title of the article was CX3CL1 promotes tumour cell by inducing tyrosine phosphorylation of cortactin in lung cancer.SDS of cas: 380843-75-4 And the article contains the following content:

It has been reported that chemokine CX3CL1 can regulate various tumors by binding to its unique receptor CX3CR1. However, the effect of CX3CL1-CX3CR1 on the lung adenocarcinoma and lung squamous cell carcinoma is still unclear. Here, we showed that CX3CL1 can further invasion and migration of lung adenocarcinoma A549 and lung squamous cell carcinoma H520. In addition, Western blot and immunofluorescence test indicated CX3CL1 up-regulated the phosphorylation level of cortactin, which is a marker of cell pseudopodium. Meanwhile, the phosphorylation levels of c-Src and c-Abl, which are closely related to the regulation of cortactin phosphorylation, are elevated. Nevertheless, the src/abl inhibitor bosutinib and mutations of cortactin phosphorylation site could inhibit the promotion effect of CX3CL1 on invasion and migration of A549 and H520. Moreover, these results of MTT, Hoechst staining and Western blot suggested that CX3CL1 had no effect on the proliferation and apoptosis of A549 and H520 in vitro. The effects of CX3CL1 were also verified by the s.c. tumor formation in nude mice, which showed that it could promote proliferation and invasion of A549 in vivo. In summary, our results indicated that CX3CL1 furthered invasion and migration in lung cancer cells partly via activating cortactin, and CX3CL1 may be a potential mol. in regulating the migration and invasion of lung cancer. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).SDS of cas: 380843-75-4

The Article related to lung cancer cx3cl1 tyrosine phosphorylation, cx3cl1, cancer, cortactin, invasion, lung, Mammalian Pathological Biochemistry: Oncology and other aspects.SDS of cas: 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On November 30, 2021, Patrick, Shruti; Gowda, Pruthvi; Lathoria, Kirti; Suri, Vaishali; Sen, Ellora published an article.HPLC of Formula: 380843-75-4 The title of the article was YAP1-mediated regulation of mitochondrial dynamics in IDH1 mutant gliomas. And the article contained the following:

Mutation of the isocitrate dehydrogenase 1 (IDH1) gene leads to the production of oncometabolite D-2-hydroxyglutarate (2-HG) from α-ketoglutarate and is associated with better prognosis in glioma. As Yes-associated protein 1 (YAP1) is an important regulator of tumor progression, its role in glioma expressing IDH1 with an R132H mutation was investigated. Diminished nuclear levels of YAP1 in IDH1 mutant glioma tissues and cell lines were accompanied by decreased levels of mitochondrial transcription factor A (TFAM). Luciferase reporter assays and chromatin immunoprecipitation were used to investigate the functionality of the TEAD2-binding site on the TFAM promoter in mediating its YAP1-dependent expression. YAP1- dependent mitochondrial fragmentation and ROS generation were accompanied by decreased telomerase reverse transcriptase (TERT) levels and increased mitochondrial TERT localization in IDH1 R132H cells. Treatment with the Src kinase inhibitor bosutinib, which prevents extranuclear shuttling of TERT, further elevated ROS in IDH1 R132H cells and triggered apoptosis. Importantly, bosutinib treatment also increased ROS levels and induced apoptosis in IDH1 wild-type cells when YAP1 was concurrently depleted. These findings highlight the involvement of YAP1 in coupling mitochondrial dysfunction with mitochondrial shuttling of TERT to constitute an essential non-canonical function of YAP1 in the regulation of redox homeostasis. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).HPLC of Formula: 380843-75-4

The Article related to yap mitochondrial dynamic idh mutant glioma, glioma, idh1, mitochondria, tert, tfam, yap1, Mammalian Pathological Biochemistry: Oncology and other aspects.HPLC of Formula: 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics